| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |
From the Edinger Institute,*
Johann-Wolfgang-Goethe
University, Frankfurt; the Max-Planck-Institute for Brain
Research,
Frankfurt; and the Institute for
Anatomy,
University of Dresden,
Dresden, Germany
The actin-binding protein ezrin has been associated with motility and invasive behavior of malignant cells. To assess the presence of this protein in human glial cells of the brain and its potential role in benign and malignant glial tumors, we studied ezrin immunoreactivity (IR), proliferation (MIB-1-IR), and apoptosis (terminal dUTP nick-end labeling) in normal human brain tissues from 10 autopsies and tissues from 115 cases of human glial tumors including astro-cytomas, ependymomas, oligodendrogliomas, and glioblastomas. We found weak staining of peripheral processes in normal human brain astrocytes and in World Health Organization grade II benign astrocytomas. Staining was markedly increased in anaplastic astrocytomas (World Health Organization grade III) and clearly strongest in glioblastomas (World Health Organization grade IV). The increase of ezrin-IR correlated significantly with increasing malignancy of astrocytic tumors (P < 0.0001). Statistical analysis revealed a stronger association with increasing malignancy for ezrin-IR than for MIB-1-IR or terminal dUTP nick-end labeling staining. Ezrin-IR was absent in normal oligodendrocytes and in oligodendrogliomas, but pronounced in normal ependymal cells and ependymomas. Ezrin-IR seems to be specific for astrocytes and ependymal glia in the normal brain. Our results indicate that ezrin-IR may provide a useful tool for the distinction of oligodendrogliomas and astrocytomas and for the grading of astrocytic tumors.
This article has been cited by other articles:
 |
|
 |
|
  H. Zeng, L. Xu, D. Xiao, H. Zhang, X. Wu, R. Zheng, Q. Li, Y. Niu, Z. Shen, and E. Li Altered Expression of Ezrin in Esophageal Squamous Cell Carcinoma J. Histochem. Cytochem., August 1, 2006; 54(8): 889 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-H. Weng, J. Ahlen, K. Astrom, W.-O. Lui, and C. Larsson Prognostic Impact of Immunohistochemical Expression of Ezrin in Highly Malignant Soft Tissue Sarcomas Clin. Cancer Res., September 1, 2005; 11(17): 6198 - 6204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Heiska and O. Carpen Src Phosphorylates Ezrin at Tyrosine 477 and Induces a Phosphospecific Association between Ezrin and a Kelch-Repeat Protein Family Member J. Biol. Chem., March 18, 2005; 280(11): 10244 - 10252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Smith, A. Cowan, and B. A. White The Low-Density Lipoprotein Receptor Is Regulated by Estrogen and Forms a Functional Complex with the Estrogen-Regulated Protein Ezrin in Pituitary GH3 Somatolactotropes Endocrinology, July 1, 2004; 145(7): 3075 - 3083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Gutmann, N. M. Hedrick, J. Li, R. Nagarajan, A. Perry, and M. A. Watson Comparative Gene Expression Profile Analysis of Neurofibromatosis 1-associated and Sporadic Pilocytic Astrocytomas Cancer Res., April 1, 2002; 62(7): 2085 - 2091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Wick, C. Grimmel, C. Wild-Bode, M. Platten, M. Arpin, and M. Weller Ezrin-Dependent Promotion of Glioma Cell Clonogenicity, Motility, and Invasion Mediated by BCL-2 and Transforming Growth Factor-{beta}2 J. Neurosci., May 15, 2001; 21(10): 3360 - 3368. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
